25/04/2022
22/11/2021
26/07/2021
20/05/2021
The COVID-19 pandemic has been a catalyst for change which has led us to revisit the way we conduct clinical trials.
16/04/2021
EuropaBio welcomes the in-depth opinion of the European Group on Ethics on the uses of genome editing and thanks the Group for raising the awareness of a technology which will enable the development of many solutions for healthy people and planet.
12/02/2021
EuropaBio sees the Directive on cross-border healthcare as an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases.
04/02/2021
EuropaBio welcomes the European Commission’s plan to begin a discussion with stakeholders to develop the EHDS.
20/10/2020
EuropaBio Position Paper on the use of Real-World Data (RWD) and Real-World Evidence (RWE) for regulatory decision-making.
19/10/2020
EuropaBio and its members would like to engage the European Commission and all relevant stakeholders in a discussion on the future use of the HE in the context of the new EU Pharmaceutical Strategy and its accompanying actions.
28/06/2018
The Pharmaceutical Industry generally welcomes the European Commission’s Proposal for a Regulation on HTA.
06/06/2017
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
27/05/2017
This document outlines the proposals put forth by EuropaBio members with regard to the changes to the Summary of Product Characteristics (SmPC) of biosimilars, which we consider would result in an enhanced level of transparency in the label.
23/01/2017
European Commission Initiative Improves Information for Patients on Biosimilar Medicines.